Curis to Present Emavusertib and BTKi Clinical Data in CNS Lymphoma at SNO.
ByAinvest
Friday, Nov 14, 2025 9:28 am ET1min read
CRIS--
Curis, a biotechnology company, will report emavusertib clinical data in Primary CNS Lymphoma and Secondary CNS Lymphoma at the Society for Neuro-Oncology annual meeting. The data will be presented in three presentations, including poster presentations and an oral presentation. Emavusertib is an IRAK4 inhibitor being developed for the treatment of relapsed/refractory PCNSL and SCNSL.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet